WO2008015695A3 - Inclusion complex of olopatadine and cyclodextrin - Google Patents

Inclusion complex of olopatadine and cyclodextrin Download PDF

Info

Publication number
WO2008015695A3
WO2008015695A3 PCT/IN2007/000199 IN2007000199W WO2008015695A3 WO 2008015695 A3 WO2008015695 A3 WO 2008015695A3 IN 2007000199 W IN2007000199 W IN 2007000199W WO 2008015695 A3 WO2008015695 A3 WO 2008015695A3
Authority
WO
WIPO (PCT)
Prior art keywords
olopatadine
cylcodextrin
inclusion complex
cyclodextrin
hydroxyalkyl
Prior art date
Application number
PCT/IN2007/000199
Other languages
French (fr)
Other versions
WO2008015695A2 (en
Inventor
Subhas Balaram Bhowmick
Ritu Nitin Laddha
Surekha Khopade
Original Assignee
Sun Pharmaceutical Ind Ltd
Subhas Balaram Bhowmick
Ritu Nitin Laddha
Surekha Khopade
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd, Subhas Balaram Bhowmick, Ritu Nitin Laddha, Surekha Khopade filed Critical Sun Pharmaceutical Ind Ltd
Publication of WO2008015695A2 publication Critical patent/WO2008015695A2/en
Publication of WO2008015695A3 publication Critical patent/WO2008015695A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to an inclusion complex of olopatadine or its pharmaceutically acceptable salt and hydroxyalkyl-ß-cylcodextrin, preferably hydroxypropyl-ß-cylcodextrin. The present invention also relates to an aqueous topical solution comprising a therapeutically effective amount of olopatadine or its pharmaceutically acceptable salt; hydroxyalkyl-ß-cylcodextrin, preferably hydroxypropyl-ß-cylcodextrin and hydroxypropyl methylcellulose in an amount sufficient to enhance the physical stability of the solution.
PCT/IN2007/000199 2006-05-15 2007-05-15 Inclusion complex of olopatadine and cyclodextrin WO2008015695A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN748MU2006 2006-05-15
IN748/MUM/2006 2006-05-15

Publications (2)

Publication Number Publication Date
WO2008015695A2 WO2008015695A2 (en) 2008-02-07
WO2008015695A3 true WO2008015695A3 (en) 2008-05-15

Family

ID=38997575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000199 WO2008015695A2 (en) 2006-05-15 2007-05-15 Inclusion complex of olopatadine and cyclodextrin

Country Status (1)

Country Link
WO (1) WO2008015695A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544922B (en) 2011-05-19 2016-08-11 愛爾康研究有限公司 High concentration olopatadine ophthalmic composition
TW201336527A (en) * 2012-02-10 2013-09-16 Alcon Res Ltd Aqueous pharmaceutical composition with enhanced stability
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005815A1 (en) * 2000-07-13 2002-01-24 Pharmacia & Upjohn Company Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
US20050004074A1 (en) * 2003-07-01 2005-01-06 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005004922A1 (en) * 2003-07-04 2005-01-20 Novartis Ag Pharmaceutical compositions comprising peranhydrocyclodextrin
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005815A1 (en) * 2000-07-13 2002-01-24 Pharmacia & Upjohn Company Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug
US20050004074A1 (en) * 2003-07-01 2005-01-06 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2005004922A1 (en) * 2003-07-04 2005-01-20 Novartis Ag Pharmaceutical compositions comprising peranhydrocyclodextrin
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations

Also Published As

Publication number Publication date
WO2008015695A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
WO2007086001A3 (en) Novel pyridine derivatives
MY154909A (en) Novel thiophene derivatives
WO2006119498A3 (en) Pharmaceutical compositions with synchronized solubilizer release
MX2010005889A (en) Novel thiophene derivatives.
WO2007147160A3 (en) Aprepitant compositions
UA93903C2 (en) Tetrahydroisoquinoline derivatives to enhance memory function
WO2006037981A8 (en) Inhibition of tumour cell migration
NO20091395L (en) New thiophene derivatives
WO2009013435A3 (en) Preservative-free prostaglandin-based ophthalmic solution
WO2007087431A3 (en) Sublingual fentanyl spray
WO2007015017A3 (en) Novel polyquinoline derivatives and the therapeutic use thereof
DK2439267T3 (en) Enzyme preparations that give a pure taste
WO2005105067A3 (en) Aqueous solutions comprising prednisolone and a cyclodextrin derivative
WO2007135527A3 (en) Benzimidazolyl compounds
MX2009004767A (en) Liquid preparation comprising a complex of pimobendan and cyclodextrin.
EP2352503A4 (en) Role of soluble upar in the pathogenesis of proteinuric kidney disease
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
WO2011014825A3 (en) Antiangiogenic small molecules and methods of use
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2008025819A3 (en) Formulations of acetylsalicylic acid or its derivatives in soft capsules, exhibiting high stability
WO2008026048A3 (en) Stable injectable pharmaceutical compositions of docetaxel
WO2007083190A8 (en) Water insoluble helichrysum extract, process for preparing the same and uses thereof
WO2006129160A3 (en) Stable aqueous oral solution of risperidone
EP2366393A3 (en) Roflumilast for the treatment of pulmonary hypertension
WO2008015695A3 (en) Inclusion complex of olopatadine and cyclodextrin

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827499

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07827499

Country of ref document: EP

Kind code of ref document: A2